Therapeutic Strategies for Diabetic Neuropathy

被引:61
|
作者
Habib, Ali A. [1 ]
Brannagan, Thomas H., III [1 ]
机构
[1] Columbia Univ, Neurol Inst, New York, NY 10032 USA
关键词
Diabetes; Peripheral neuropathy; Cardiac autonomic neuropathy; Glycemic control; Cardiovascular risk factors; CARDIAC AUTONOMIC NEUROPATHY; IMPAIRED GLUCOSE-METABOLISM; ALDOSE REDUCTASE INHIBITOR; NERVE GROWTH-FACTOR; RISK-FACTORS; PERIPHERAL NEUROPATHY; DOUBLE-BLIND; SENSORY NEUROPATHY; GENE-TRANSFER; PITTSBURGH EPIDEMIOLOGY;
D O I
10.1007/s11910-010-0093-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Diabetes is the leading cause of peripheral neuropathy globally. Duration of diabetes, glycemic control, and preexisting cardiovascular risk factors independently correlate with the development and progression of diabetic peripheral neuropathy as well as cardiovascular autonomic neuropathy. The pathogenesis of diabetic neuropathy remains unclear, although insulin resistance, oxidative stress, mitochondrial dysfunction, abnormal glucose metabolism, advanced glycation end products, neurotrophic factors, and protein kinase C activation all may play a role. Strict glycemic control remains the only available treatment option, although other treatments are in development. Multiple options are available for symptom management. In this article, we review factors associated with development and progression of diabetic neuropathy and discuss available treatment options.
引用
收藏
页码:92 / 100
页数:9
相关论文
共 50 条
  • [41] Flavonoids as Potential Therapeutic Agents for the Management of Diabetic Neuropathy
    Sood, Ankita
    Kumar, Bimlesh
    Singh, Sachin Kumar
    Prashar, Pankaj
    Gautam, Anamika
    Gulati, Monica
    Pandey, Narendra Kumar
    Melkani, Indu
    Awasthi, Ankit
    Saraf, Subhini A.
    Vidari, Giovani
    Ozdemir, Mehmet
    Hussain, Faiq Hama Saeed
    Anwar, Esra Tariq
    Ameen, Muath Sheet Mohammed
    Gupta, Saurabh
    Porwal, Omji
    CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (42) : 5468 - 5487
  • [42] Therapeutic potential of PKC inhibitors in painful diabetic neuropathy
    Kamei, J
    Mizoguchi, H
    Narita, M
    Tseng, LF
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (09) : 1653 - 1664
  • [43] Minocycline with aspirin: a therapeutic approach in the treatment of diabetic neuropathy
    Bhatt, L. K.
    Veeranjaneyulu, Addepalli
    NEUROLOGICAL SCIENCES, 2010, 31 (06) : 705 - 716
  • [44] Recent Advances in Diagnostic Strategies for Diabetic Peripheral Neuropathy
    Won, Jong Chul
    Park, Tae Sun
    ENDOCRINOLOGY AND METABOLISM, 2016, 31 (02) : 230 - 238
  • [45] NF- ĸ B axis in diabetic neuropathy, cardiomyopathy and nephropathy: A roadmap from molecular intervention to therapeutic strategies
    Rezaee, Aryan
    Rahmanian, Parham
    Nemati, Amirreza
    Sohrabifard, Farima
    Karimi, Fatemeh
    Elahinia, Ali
    Ranjbarpazuki, Ali
    Lashkarbolouki, Rozhin
    Dezfulian, Sadaf
    Zandieh, Mohammad Arad
    Salimimoghadam, Shokooh
    Nabavi, Noushin
    Rashidi, Mohsen
    Taheriazam, Afshin
    Hashemi, Mehrdad
    Hushmandi, Kiavash
    HELIYON, 2024, 10 (09)
  • [46] Interconnections between diabetic corneal neuropathy and diabetic retinopathy:diagnostic and therapeutic implications
    Mingyi Yu
    Faith Teo En Ning
    Chang Liu
    YuChi Liu
    Neural Regeneration Research, 2025, 20 (08) : 2169 - 2180
  • [48] Mexiletine - A review of its therapeutic use in painful diabetic neuropathy
    Jarvis, B
    Coukell, AJ
    DRUGS, 1998, 56 (04) : 691 - 707
  • [49] Nrf2: a potential therapeutic target for diabetic neuropathy
    Kumar, Anil
    Mittal, Ruchika
    INFLAMMOPHARMACOLOGY, 2017, 25 (04) : 393 - 402
  • [50] Molecular Insights on the Therapeutic Effect of Selected Flavonoids on Diabetic Neuropathy
    Sivakumar, Ponnurengam Malliappan
    Prabhakar, Pranav Kumar
    Cetinel, Sibel
    Neelakandan, R.
    Prabhawathi, Veluchamy
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2022, 22 (14) : 1828 - 1846